Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P12107
UPID:
COBA1_HUMAN
Alternative names:
-
Alternative UPACC:
P12107; B1ASK7; D3DT73; E9PCU0; Q14034; Q149N0; Q9UIT4; Q9UIT5; Q9UIT6
Background:
Collagen alpha-1(XI) chain plays a pivotal role in fibrillogenesis, guiding the lateral growth of collagen II fibrils. This process is crucial for maintaining the structural integrity and function of various tissues.
Therapeutic significance:
Linked to diseases such as Stickler syndrome 2, Marshall syndrome, Fibrochondrogenesis 1, and autosomal dominant deafness, DFNA37, understanding the role of Collagen alpha-1(XI) chain could open doors to potential therapeutic strategies.